Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Liabilities and Shareholders Equity (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $687.5 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity rose 19.19% to $687.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 billion through Dec 2025, up 12.66% year-over-year, with the annual reading at $687.5 million for FY2025, 19.19% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $687.5 million at Centessa Pharmaceuticals, up from $448.3 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $687.5 million in Q4 2025, with the low at $328.2 million in Q1 2024.
  • Average Liabilities and Shareholders Equity over 4 years is $476.9 million, with a median of $463.8 million recorded in 2022.
  • The sharpest move saw Liabilities and Shareholders Equity crashed 30.63% in 2023, then skyrocketed 61.57% in 2024.
  • Over 4 years, Liabilities and Shareholders Equity stood at $444.3 million in 2022, then dropped by 18.92% to $360.2 million in 2023, then surged by 60.11% to $576.8 million in 2024, then rose by 19.19% to $687.5 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $687.5 million, $448.3 million, and $492.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.